Eli Lilly to Build $2.8 Billion Drug Facility in North carolina
Table of Contents
Concord, NC – April 26, 2024 – Eli Lilly and Company announced today a significant investment of $2.8 billion to establish a new pharmaceutical manufacturing facility in Concord, North Carolina.The facility will focus on the production of injectable drugs, particularly in the rapidly evolving market for obesity treatments. The facility will be capable of producing a range of injectable products, but retatrutide is a key focus.
Could retatrutide revolutionize weight management? Clinical trial data suggests retatrutide could offer substantial weight loss benefits, perhaps exceeding those seen with currently available medications. The drug is still under investigation, and its ultimate efficacy and safety profile remain to be determined.
Project Timeline and Economic Impact
Construction of the 2.7 million-square-foot facility is scheduled to begin this year, with the first production expected to commence in 2027. The project is anticipated to generate approximately 2,100 jobs in the Concord area,providing a considerable economic boost to the region. North Carolina Governor Roy Cooper hailed the investment as a testament to the state’s growing life sciences sector.
The new site will be located on a 90-acre plot in Concord, and will include buildings for manufacturing, quality control laboratories, and warehousing. Eli Lilly plans to incorporate enduring design principles into the facility’s construction and operation.
Expanding Capacity to Meet Demand
The demand for weight-
Keep reading
